Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer ...

Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...

Shares of Prelude Therapeutics rose after the company said it has received Food and Drug Administration approval to proceed with a Phase 1 study for blood-cancer treatment. Shares were up 9.4% at ...

Members of the Mountain Rail Coalition gathered virtually on Jan. 22 to celebrate key milestones, strategize on sustaining ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study ...

NTLA stock faces binary risk: success could unlock multi-billion dollar markets, while setbacks may erase hundreds of ...

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

The company noted that its Phase 2 community study, known as POSITS, has started with the first participants being dosed in ...

One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.